Previous Article | Next Article 
Journal of Virology, September 2000, p. 7824-7833, Vol. 74, No. 17
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Characterization of Chemokine Receptor Utilization of Viruses in
the Latent Reservoir for Human Immunodeficiency Virus Type 1
Theodore
Pierson,1
Trevor L.
Hoffman,2
Joel
Blankson,1
Diana
Finzi,1
Karen
Chadwick,3
Joseph B.
Margolick,3
Christopher
Buck,1
Janet D.
Siliciano,1
Robert W.
Doms,2 and
Robert F.
Siliciano1,*
Department of Medicine, Johns Hopkins
University School of Medicine,1 and
Department of Molecular Microbiology and Immunology, Johns
Hopkins School of Hygiene and Public Health,3
Baltimore, Maryland 21205, and Department of Pathology and
Laboratory Medicine, University of Pennsylvania, Philadelphia,
Pennsylvania 191042
Received 13 January 2000/Accepted 22 May 2000
 |
ABSTRACT |
Latently infected resting CD4+ T cells provide a
long-term reservoir for human immunodeficiency virus type 1 (HIV-1) and
are likely to represent the major barrier to virus eradication in patients on combination antiretroviral therapy. The mechanisms by which
viruses enter the latent reservoir and the nature of the chemokine
receptors involved have not been determined. To evaluate the phenotype
of the virus in this compartment with respect to chemokine receptor
utilization, full-length HIV-1 env genes were cloned from
latently infected cells and assayed functionally. We demonstrate that
the majority of the viruses in the latent reservoir utilize CCR5 during
entry, although utilization of several other receptors, including
CXCR4, was observed. No alternative coreceptors were shown to be
involved in a systematic fashion. Although R5 viruses are present in
the latent reservoir, CCR5 was not expressed at high levels on resting
CD4+ T cells. To understand the mechanism by which R5
viruses enter latent reservoir, the ability of an R5 virus, HIV-1 Ba-L,
to infect highly purified resting CD4+ T lymphocytes from
uninfected donors was evaluated. Entry of Ba-L could be observed when
virus was applied at a multiplicity approaching 1. However, infection
was limited to a subset of cells expressing low levels of CCR5 and
markers of immunologic memory. Naive cells could not be infected by an
R5 virus even when challenged with a large inoculum. Direct cell
fractionation studies showed that latent virus is present predominantly
in resting memory cells but also at lower levels in resting naive
cells. Taken together, these findings provide support for the
hypothesis that the direct infection of naive T cells is not the major
mechanism by which the latent infection of resting T cells is established.
 |
INTRODUCTION |
The demonstration of resting
CD4+ T lymphocytes carrying replication-competent human
immunodeficiency virus type 1 (HIV-1) genomes in patients successfully
treated with highly active antiretroviral therapy (HAART) identifies
the latent infection of these cells as an important mechanism of viral
persistence (12, 20, 43). Although present at a low
frequency, this latent reservoir persists for extremely long periods of
time in the face of aggressive antiviral therapy
(t1/2, 6 to 44 months) (8, 19, 51).
Thus, these latently infected cells represent a serious obstacle to
virus eradication.
While the clinical importance of the latent infection of resting
CD4+ lymphocytes has been clearly demonstrated, the
mechanisms that govern the formation of this latent reservoir are less
clear. The existence of this reservoir can best be explained by
considering the infection of CD4+ T cells in the context of
the normal physiology of T-cell activation (reviewed in reference
33). Naive CD4+ T cells exit the thymus
and enter the peripheral lymphoid tissues, where they persist in a
resting state until they encounter cognate antigen. Following initial
exposure to antigen, naive T cells undergo blast transformation and
enter the cell cycle. Activation results in an increase in the size of
nucleotide pools and increased expression of sets of molecules
including transcription factors, effector molecules such as cytokines,
and cell surface proteins such as cytokine receptors and adhesion
molecules (15). After several rounds of division, some of
the activated cells exit the cell cycle, lose expression of activation
markers such as HLA-DR, and revert to a resting state in which they
persist as memory T cells capable of responding to subsequent exposures
to the initiating antigen. An appealing model for the formation of the
latent reservoir involves the infection of activated CD4+
lymphocytes, which at some frequency survive both the cytopathic effects of the virus and antiviral immune responses. A fraction of
these infected cells may exit the cell cycle into a quiescent state,
carrying with them an integrated copy of the HIV-1 genome. The finding
that the majority of integrated DNA in resting lymphocytes appears to
be in the memory CD4+ T-lymphocyte subset provides evidence
in support of this hypothesis (9).
The direct infection of quiescent lymphocytes may also play a role in
the establishment of the latent compartment. Unlike the situation in
activated CD4+ cells, the infection of resting lymphocytes
is nonproductive due to a block upstream of the integration event. This
block has been suggested to arise from an inability to complete the
reverse transcription reaction (25, 46, 47) or a failure to
import the preintegration complex into the nucleus (38).
Previous work clearly demonstrates that this preintegration form of
latent infection is labile, but if the infected cell is activated soon
after infection, productive infection ensues (5, 47).
Interestingly, recent experiments using pseudotyped HIV-1 vectors
demonstrate that certain cytokines provide signals that make resting
cells permissive for virus integration and gene expression
(41). This is in agreement with previous work demonstrating
virus propagation in purified resting cells treated with combinations
of stimulatory cytokines (44). The proinflammatory
environment of HIV-1 infection may provide a suitable milieu for
cytokine-driven progression from the labile preintegration state of
latency to stable latent infection. Thus, infected resting cells may
transit from a labile preintegration state to a stable form of latency
in both antigen-dependent and antigen-independent mechanisms and may
play a role in the establishment of the stable latent reservoir of
HIV-1 provirus in resting T cells.
One approach to understanding the establishment of the latent reservoir
for HIV-1 involves an analysis of the chemokine receptors utilized by
viruses that enter latency. The phenotype of the envelope (Env) protein
of virus in the latent compartment may reflect the path by which
infection in quiescent T cells was established. Latent infection of
resting T cells occurs very soon after transmission and cannot be
blocked by early treatment (10, 19, 51). This early
establishment suggests an involvement of CCR5 simply because R5 viruses
predominate during the acute phase of the disease and are clearly
involved in transmission (reviewed in reference 1). However, the nature of the chemokine receptors utilized by viruses in
the latent reservoir has not been previously determined and may involve
additional coreceptor molecules. To identify additional coreceptors
involved in establishing a latent infection, we cloned full-length
functional env genes of virus in the latent reservoir and
assayed their chemokine receptor utilization.
The ability of viruses utilizing CCR5 to enter highly purified resting
cells has not been demonstrated. In fact, previous in vitro studies
suggest that the infection of resting lymphocytes lacking CD25 by an R5
virus cannot occur (7). A consequence of this is that entry
into the latent compartment by R5 viruses should occur only via an
activated intermediate, as discussed above. If resting lymphocytes are
indeed resistant to infection by R5 viruses, the presence of these
viruses within the reservoir could provide support for the hypothesis
that entry of the virus into the reservoir occurs via an activated T
cell expressing both CCR5 and CXCR4. Furthermore, since the large
majority of lymphocytes in the periphery are resting, the inability of
R5 viruses to enter quiescent cells would have implications for
pathogenesis and viral dynamics. To complement our analysis of
coreceptor utilization, we have assessed the ability of viruses using
CCR5 to directly infect highly purified populations of resting
CD4+ lymphocytes. Together these studies provide new
insights into the establishment of the latent reservoir.
 |
MATERIALS AND METHODS |
PCR amplification and cloning of full-length env
genes.
Highly purified resting CD4+ T lymphocytes were
isolated from the peripheral blood mononuclear cells (PBMC) of eight
patients on HAART as previously reported (20). One
additional patient successfully treated with HAART was acquired
separately for study because of documented history of X4 virus in the
circulation. Latent virus was cultured from this patient as described
(20). To detect and clone full-length envelope genes from
the genomic DNA of these resting T cells, a novel nested PCR strategy
employing a thermostable polymerase cocktail with proofreading activity was performed. A mass of 500 ng of genomic DNA was amplified in a
reaction containing 1 µM each of outer primer (sense,
5'-ATGGCAGGAAGAAGCGGAGACAG-3'; antisense,
5'-TGTGTAGTTCTGCCAATCAGGGAAGTAGCCTTGTG-3') 200 µM each of
the four deoxynucleoside triphosphates, buffer containing 1.5 mM
MgCl2, and 3.5 U of Expand High Fidelity polymerase
cocktail (Boehringer Mannheim). A 3-min hot start at 94°C was
performed, followed by 25 cycles of 94°C for 30 s, 65°C for
30 s, and 68°C for 3 min. An additional 5 s were added to
the extension step of the last 15 cycles of this reaction. A final
extension at 68°C was performed for 7 min. An aliquot of the reaction
product was diluted 1:4 in distilled water for use in a second reaction
with inner primers (sense,
5'-GATAGACGCGTAGAAAGAGCAGAAGACAGTGGCAATG-3'; antisense,
5'-CCTTGTCCGGCGGCCGCCTTAAAGGTACCTGAGGTCTGACTGG-3') of 20 cycles of 94°C for 30 s, annealing at 68°C for 30 s, and 68°C for 3 min. Again, an additional 5 s of extension were added during the last 10 cycles of the reaction. A 7-min final extension was
also performed. PCR products were gel purified (Qiagen), digested with
NotI and MluI, and cloned into the pCI-PRE vector
as described (C. Buck and R. F. Siliciano, submitted for
publication). The resulting constructs were transformed into
Escherichia coli JM109 competent bacteria and grown at
30°C to minimize recombination and bacterially induced mutagenesis
within env. Because our strategy did not distinguish
defective genomes from those competent to replicate, env
genes from replication-competent virus were also cloned. Viruses
isolated from resting CD4+ T cells of three patients on
HAART were used to infect phytohemagglutinin-stimulated, CD8-depleted
primary lymphoblasts. DNA was then isolated and used as a template for
the PCR and cloning strategy described above.
Functional activity of env clones from the latent
reservoir.
env clones were assayed for functional activity
as measured by the ability to utilize a panel of chemokine receptors in
a previously described luciferase reporter virus infection assay (17). Briefly, Env and NL-luc E
R
plasmids were transfected into 293T cells using CaPO4.
Viral supernatants were harvested 2 days posttransfection, cleared of cell debris by low-speed centrifugation, and used to infect feline CCC
cells transfected with CD4 and various HIV-1 coreceptors. Infection of
target cells by pseudotyped virus leads to expression of luciferase,
which was quantified in cell lysates 2 to 3 days following addition of
virus. To maximize our ability to sample viruses in the latent
compartment, analysis was performed on multiple clones representing
multiple independent PCR amplifications.
Isolation and analysis of highly purified resting T cells.
Resting CD4+ lymphocytes were prepared using a modification
of a previously published purification strategy (9, 11, 20). PBMC from seronegative donors were prepared by centrifugation on
Ficoll-Hypaque gradients. Monocytes were removed by adherence during
overnight culture in RPMI 1640 supplemented with 10% fetal calf serum,
100 U of penicillin per ml, 100 µg of streptomycin per ml, and 2 mM
glutamine (minimal medium [MM]). Initial enrichment for resting
CD4+ T cells was achieved by a bead depletion strategy.
Cells were incubated for 30 min on ice with a cocktail of monoclonal
antibodies against cell surface markers expressed on other cell
lineages (CD8, CD19, CD16, and CD14) or activated CD4+ T
cells (CD69, CD25, and HLA-DR). Excess antibody was removed by washing
in phosphate-buffered saline (pH 7.2) supplemented with 2% fetal calf
serum, 0.1% glucose, 100 U of penicillin per ml, 100 µg of
streptomycin per ml, and 12 mM HEPES (pH 7.2). Cells carrying bound
antibody were removed by incubation with magnetic beads conjugated to
sheep anti-mouse immunoglobulin G (Dynal) at 4°C for 25 min, followed
by magnetic separation. The resulting fractionated cells were stained
with phycoerythrin (PE)-conjugated OKT4 (Ortho-immune Diagnostics) and
Tri-Color (TC)-labeled anti-HLA-DR antibody (Caltag) for 30 min on ice
in preparation for sorting. OKT4 does not block infection by HIV-1.
Cells staining CD4+ and DR
were collected
using an Elite cell sorter (Coulter). Isolation of quiescent
populations depleted of either CD45 RA+ or CD45
RO+ cells was performed as described above by including the
relevant fluorescein isothiocyanate (FITC)-conjugated monoclonal
antibodies in both the depletion and sorting steps. Sorting was then
performed by collecting cells positive for CD4+ and
negative for HLA-DR
and the relevant CD45 isoform. This
strategy allowed the exclusion of cells expressing both RO and RA
isoforms from either population.
The fraction of highly purified resting cells expressing CCR5 was
enumerated using three-color fluorescence-activated cell sorting (FACS)
analysis. Two hundred thousand cells were stained with the
FITC-conjugated monoclonal antibody against CCR5 (2D7; Pharminagen) in
conjunction with the PE- and Tri-Color-labeled antibodies against CD4
and HLA-DR (respectively) described above. The fraction of resting
cells expressing CCR5 was determined by gating on CD4+
lymphocytes lacking HLA-DR.
Infection of highly purified resting T lymphocytes.
High-titer HIV-1 stocks were obtained commercially (ABI) and treated
with DNase (Boehringer Mannheim) in the presence of 1 mM
MgCl2 for 30 min at 37°C. DNase treatment was required to
remove contaminating DNA in the stock arising from cell death and lysis during virus production. Between 5 × 105 and 1 × 106 purified resting lymphocytes were resuspended in 100 µl of MM and infected at a multiplicity of infection (MOI) of either
0.1 or 1. To account for intravirion reverse transcription products (27, 40, 48-50) and contaminating DNA in the viral stocks, an aliquot of virus was heat inactivated at 70°C for 30 min, and an
equivalent amount was applied to resting cells. Three hours following
application of the virus, the cells were washed in 1 ml of
trypsin-EDTA. A second 1-ml volume of 1× trypsin was added and
incubated at 37°C for 10 min. A final wash with 1 ml of MM was
performed. Cells were cultured in MM where indicated, followed by
lysis. Cell lysis was performed in 200 µl of PCR lysis buffer containing 100 mM KCl, 20 mM Tris (pH 8.3), 0.1% NP-40, and 500 µg
of proteinase K per ml (17).
HIV-1 entry was detected using a modification of the PCR strategy
previously described by Chen and colleagues (
46). Since
the
entry of viruses into resting cells is complicated by the
protracted
kinetics of reverse transcription in quiescent cells,
the generation of
both early (long terminal repeat [LTR]) and
late (LTR-Gag) products
of the reaction was monitored using the
previously published primer
pairs M667-AA55 and M667-M661, respectively.
These reactions were
performed using chemistry similar to that
described above and cycling
the reaction between 94 and 65°C.
Products of the reaction were
subjected to 2% agarose electrophoresis
followed by alkaline transfer
to nitrocellulose and hybridization
with an end-labeled oligonucleotide
probe. Products of reactions
employing M667 and AA55 were detected with
a specific end-labeled
oligonucleotide probe (5'-GTG CTT CAA GTA GTG
TGT GCC C-3'), while
those amplified by M667 and M661 were detected
with AA55. To control
for the relative number of cells in each lysate,

-globin was
amplified and detected by Southern hybridization as
described
(
9).
Quantitation of viruses in the latent reservoir.
The
frequency of cells harboring latent HIV-1 among purified resting naive
and resting memory subsets of CD4+ T cells was evaluated
using a previously described limiting-dilution culture assay
(19). These studies were carried out on blood samples from
previously characterized patients on combination therapy who had
undetectable plasma virus levels. This ensures that the latent viruses
detected are derived from the stable latent reservoir (19).
Results are expressed as infectious units per million (IUPM) resting
CD4+ T cells.
 |
RESULTS |
Cloning and characterization of functional envelope genes from
quiescent lymphocytes of patients on HAART.
To identify the
phenotype of env from viruses resident in latently infected
resting T lymphocytes of patients on HAART, viral envelopes were cloned
from resting T cells from selected patients and assayed for their
ability to utilize a panel of chemokine receptors in a functional
assay. Patients who were being treated with combinations of three to
five antiretroviral drugs, including a protease inhibitor, and who had
undetectable plasma HIV-1 RNA (<200 copies/ml) were selected for
study. The characteristics of the patient population are summarized in
Table 1. In patients with effective
suppression of viral replication, viruses isolated from resting
CD4+ T cells are likely to be derived from cells with
stably integrated HIV-1 DNA (20). DNA was isolated from
purified resting CD4+ cells and used as the template in a
novel nested PCR strategy for the amplification and cloning of the
full-length env gene. This assay could detect as few as 50 copies of env in a background of 500 ng of
HIV-1
genomic DNA (data not shown). Approximately 50% of
the clones studied were functional in cell fusion (not shown) or
pseudotyping experiments.
The chemokine receptor utilization of 34 clones from nine patients was
determined using previously described pseudotyping
technology
(
13). The vast majority of clones assayed could infect
CD4
+ target cells expressing CCR5 but not cells expressing
CXCR4 (Table
2). However, clones
representing both the X4 and R5/X4 viral
phenotypes were identified. To
decrease the chance that the low
frequency of X4 virus identified
during our studies was a consequence
of inadequate sampling, envelopes
derived from independent cloning
experiments were analyzed. Only
envelopes from patients 12 and
56 had the capacity to utilize CXCR4 in
the absence of CCR5. Interestingly,
studies performed prior to the
administration of HAART revealed
that the phenotype of viruses in the
circulation of patient 56
included those capable of utilizing CXCR4.
The
env genes cloned
from the resting T cells of this
patient utilized either CCR5
or CXCR4 in luciferase reporter virus
infections. That R5 virus
was detected in the reservoir years after the
detection of X4
virus in the peripheral blood highlights the capacity
of the reservoir
to preserve viruses representing the complete life
history of
the infection within an individual (Table
2). Envelopes from
patient 10 were dual tropic, capable of utilizing both CCR5 and
CXCR4.
Other coreceptors, including V28, GPR15, STRL33, and APJ,
were able to
support reporter virus entry in a few instances,
but the reduced
efficiency and low frequency of usage of alternate
receptors suggest
that they do not play a major role in establishment
of the latent virus
reservoir. The phenotype of clones from virus
cultured from the latent
reservoir of patients 14, 16, and 56
could not be distinguished from
the
env genes of viruses cloned
directly from the DNA of
resting cells of these patients, indicating
that direct sampling of
proviral DNA in purified resting CD4
+ T cells provides a
representative picture of the replication-competent
viruses harbored in
the latent reservoir.
Expression of CCR5 on resting lymphocytes.
The results
presented above suggest that R5 viruses predominate in the latent
reservoir for HIV-1 in resting CD4+ T cells. To understand
this finding with respect to the capacity of R5 viruses to directly
infect resting T cells, we studied the expression of CCR5 on resting
T-cell populations of uninfected donors. Earlier studies of PBMC
demonstrated CCR5 expression on a subset of cells expressing markers of
both activation and memory (CD26+ and CD45RO+),
while CXCR4 was shown to have a reciprocal pattern, being expressed predominantly on naive cell populations (CD45 RA+) (3,
9). Recent four-color FACS analysis of PBMC demonstrated the
expression of CXCR4 on both naive and memory T-cell subsets, while CCR5
was found to be absent on naive T cells (35). Interpretation of the published data is complicated by the failure of some studies to
distinguish clearly between resting CD4+ T cells, which can
harbor latent virus, and activated T cells, which are fully permissive
for viral replication. Making use of the same rigorous cell
purification procedure used in the delineation of the latent reservoir,
we isolated resting CD4+ T cells that were negative for
expression of the activation markers HLA-DR, CD25, and CD69. The level
of CCR5 on these highly purified resting CD4+ T lymphocytes
was then measured. Considering what is now known about the factors
regulating its promoter, high levels of expression of CCR5 on quiescent
lymphocytes would not be predicted (22, 31). In agreement
with these observations, highly purified resting cells consistently
demonstrated lower levels of CCR5 than partially purified or unpurified
PBMC from the same donor (Fig. 1). The percentage of cells expressing CCR5 was a function of the fraction of
cells expressing HLA-DR, suggesting that among PBMC, most of the cells
expressing CCR5 coexpress markers of activation. This finding
highlights the association between CCR5 expression and markers of
activation. For all individuals studied, less than 6.3% of highly
purified resting CD4+ T cells (containing <1%
CD4+ DR+ cells) had detectable expression of
CCR5. Thus, CCR5 expression can be detected at low levels on only a
small fraction of the resting CD4+ T-lymphocyte population
known to harbor latent HIV-1.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 1.
CCR5 expression on resting CD4+ T cells at
various stages of purification. Highly purified resting
CD4+ T cells were isolated from the peripheral blood of
HIV-negative donors by removing unwanted cell lineages and activated
CD4+ T cells through sequential bead depletion and cell
sorting procedures. HLA-DR was used as a marker of activation. The
purity of resting CD4+ T cells was invariably greater than
99%. Cells at multiple points of the procedure were stained for CCR5
expression using a FITC conjugate of the anti-CCR5 monoclonal 2D7.
|
|
Infection of quiescent CD4+ T lymphocyte populations is
inefficient when mediated by CCR5 due to low surface expression of the
coreceptor.
A small number of resting CD4+ T cells
express CCR5 at levels that can be detected by flow cytometry. To
determine whether this level of coreceptor is sufficient to mediate
infection, the ability of the R5 isolate Ba-L to enter resting T
lymphocytes was measured and compared to the ability of the X4 virus
HIV-1 IIIb to infect these cells. Previous studies demonstrate a
relationship between the amounts of CCR5 and CD4 present on the surface
of a cell required for infection by an R5 virus, concluding that in the
presence of high levels of CD4, low-level expression of CCR5 could
mediate infection (34, 45). The level of CXCR4 on highly
purified resting T cells is sufficient for entry by X4 viruses (9,
25). Since the infection of resting lymphocytes is nonproductive
due to either a block in nuclear import (4, 38) or
incomplete reverse transcription (25, 46, 47), entry of
HIV-1 was detected by a modification of a previously published
PCR-based entry assay which detects the products of reverse
transcription (46).
Several control experiments were performed to ensure that the signals
detected represented infection rather than the products
of intravirion
reverse transcription (
27,
40,
48-50) or contaminating
DNA
in the virus stock. The generation of HIV-1 DNA-specific signals
following infection could be blocked by inclusion of monoclonal
antibodies to CD4 or the gp41 peptide fusion inhibitor DP372 (data
not
shown) (
42). Furthermore, the reaction detecting complete
reverse transcription products could be blocked by the addition
of
zidovudine prior to infection (data not shown). In addition,
as is
discussed below, the time-dependent increase in the strength
of the
signals demonstrated that the assay was detecting products
of reverse
transcription being generated in infected cells following
virus
entry.
Using this assay, entry of HIV-1 Ba-L and HIV-1 IIIb into quiescent
CD4
+ T lymphocytes purified from the blood of seronegative
donors
was measured. Purified cells were universally greater than 99%
pure, as judged by the absence of contaminating activated cells
expressing HLA-DR. When infections were performed at a multiplicity
of
0.1, a significant and reproducible difference in the ability
of these
two viruses to enter resting cells was observed. Entry
of IIIb could be
demonstrated at a lower multiplicity than that
of the R5 virus Ba-L
(Fig.
2A). This result likely reflects
the
large difference in expression of CXCR4 and CCR5 coreceptors on
resting cells. In some donors, infection with Ba-L at an MOI of
0.1 did
not yield significant entry by our assay, consistent with
the reported
variability of expression of CCR5 from donor to donor.
However, the
resting lymphocytes of all donors studied could be
infected by R5
viruses at an MOI of 1, ruling out an absolute
block to infection of
resting lymphocytes by a virus utilizing
CCR5 (Fig.
2B). These
experiments were performed in duplicate
on samples from four different
donors. The titers of the Ba-L
and IIIb stocks used were equivalent, as
evidenced by the fact
that both viruses could infect activated
CD4
+ T cells with similar efficiencies (data not shown).

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 2.
Levels of CCR5 on highly purified resting T lymphocytes
are sufficient to mediate infection by the R5 virus Ba-L. The ability
of highly purified resting cells to be infected with the R5 virus HIV-1
Ba-L and the X4 virus HIV-1 IIIb was determined. Cells were infected at
an MOI of 0.1 (A) or 1.0 (B). After incubation for the indicated time
at 37°C, cells were lysed, and entry was monitored by PCR assay for
early (LTR) and late (LTR-Gag) products of reverse transcription as
described (46). In control lanes, virus was heat-inactivated
(HI) before infection. The sensitivity of the PCR in each experiment
was assayed using a series of ACH-2 dilutions as a target for the PCR
described above. A fragment of the -globin gene was amplified to
normalize for the number of cells used in each PCR experiment.
Infection experiments were performed at least twice on cells from four
different donors.
|
|
The coreceptor utilization of Ba-L has been characterized extensively
and has been shown to be almost exclusively CCR5 (Table
2) (
16,
32). To rule out the possibility that the infection
of resting
cells by HIV-1 Ba-L shown in our previous experiments
was mediated by
an alternative or undiscovered coreceptor, we
attempted to block
infection by preincubating the cells with monoclonal
antibodies to
CCR5. A cocktail of anti-CCR5 monoclonals (R&D Technologies)
blocked
infection with an efficiency that roughly equaled that
of anti-CD4.
Neither an irrelevant antibody nor a monoclonal antibody
against CXCR4
was able to diminish the entry of Ba-L (data not
shown).
Infection of quiescent lymphocytes by an R5 virus can be eliminated
by removing cells expressing CD45RO.
To further characterize the
subset of resting cells permissive for infection by Ba-L, highly
purified quiescent cells were further depleted of markers associated
with a naive or memory phenotype. Cells obtained using a modification
of a previously described depletion and sorting strategy were greater
than 99% free of contaminating cells expressing HLA-DR and the
unwanted CD45 isoform (Fig. 3). The
resulting cells were infected at a multiplicity of 1 with Ba-L. PCR
analysis clearly demonstrated that the infection of quiescent
lymphocytes is restricted to subsets containing cells expressing CD45RO
(Fig. 4). Thus, CCR5-utilizing isolates
can enter a subset of resting memory T cells but not naive cells.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 3.
Purification of naive and memory resting
CD4+ T cell. PBMC from HIV-1-negative donors were subjected
to magnetic depletion using monoclonal antibodies to CD8, CD19, CD16,
CD14, CD69, CD25, HLA-DR, and either CD45 RA or RO. Cells were sorted
for those expressing CD4 while lacking expression of either HLA-DR or
the relevant CD45 isoform. Sorted populations contained less than 1.0%
contaminants expressing HLA-DR or the inappropriate CD45 isoform.
|
|

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 4.
Infection of resting cells by R5 viruses is restricted
to those expressing markers of immunologic memory. Resting
CD4+ lymphocytes depleted of either naive or memory subsets
were obtained and infected with HIV-1 Ba-L at a multiplicity of 1.0. Infection was monitored over the course of 3 days. Infection was
monitored through the detection of the products of reverse
transcription as described using M661 and M667 (46). The
sensitivity of the PCR in each experiment was assayed using a series of
ACH-2 dilutions as a target for the PCR against the LTR-Gag junction.
Amplification of -globin was performed to demonstrate the presence
of an equal mass of DNA in each sample. This experiment was performed
on samples from two donors with identical results.
|
|
Latent HIV-1 can be found in resting memory CD4+ T
cells in vivo and to a lesser extent in naive cells.
Given that
the R5 viruses that comprise the latent reservoir in most patients
cannot directly infect naive resting CD4+ T cells, it was
of interest to determine whether latent virus could be isolated from
the naive subset of resting CD4+ T cells obtained from
infected individuals. Using a previously described purification scheme
that yields naive and memory CD4+ T cell subsets that have
<1% contamination with the other subset or with activated cells, the
frequency of cells harboring latent, replication-competent HIV-1 was
measured by limiting-dilution cultures (Table
3). In most patients, latent virus was
found predominantly in the memory subset, consistent with the idea that latently infected cells arise through infection of activated cells, which then revert to a resting memory state. However, for some patients, latent virus could also be isolated from naive cells at a
lower frequency. When considered in the context of the above studies
demonstrating the inability of R5 viruses to enter naive cells, these
results suggest that latent infection is established in naive cells
through a mechanism other than direct infection of the cells while they
are in a resting, naive state.
 |
DISCUSSION |
The establishment of replication-competent HIV-1 genomes within
the resting CD4+ T lymphocytes of infected individuals is
an important mechanism of viral persistence and represents a major
barrier to HIV-1 eradication with antiretroviral drugs (12, 20,
43). The manner in which this stable infection is established can
only be inferred. HIV-1 replicates most efficiently in activated
CD4+ T lymphocytes which express high levels of CD4, CXCR4,
and CCR5. One model suggests that at some frequency, an infected
activated T lymphocyte may exit the cell cycle, enter a quiescent
state, and circulate as a latently infected resting memory
CD4+ T cell. This model is supported by the finding that
the majority of stable latent virus in resting cells can be found in
memory cells. In this study, the mechanisms by which viruses enter the latent reservoir in resting CD4+ T cells has been evaluated
through an analysis of the patterns of chemokine receptor utilization
by viruses in the reservoir, of the distribution of these viruses among
naive and memory subsets of resting CD4+ T cells, and of
the direct entry of X4 and R5 viruses into these subsets.
The contribution of the direct infection of resting cells to the
establishment of the latent reservoir is not clear. Since, at any given
time, the majority of lymphocytes are in a quiescent state, resting
lymphocytes likely represent a major target for infection by HIV-1.
Previous studies characterizing the ability of HIV-1 to enter
unstimulated CD4+ T-cell populations involved the use of
laboratory-adapted strains of HIV-1 that utilize CXCR4 (21, 23,
36, 38, 39, 47). Subsequent studies using highly purified resting
T cells confirmed these initial findings (9, 25). Although
several reports include experiments demonstrating the capacity of R5
isolates to infect unpurified, unstimulated peripheral blood
populations (39, 46, 47), rigorous analysis of the capacity
of R5 viruses to enter highly purified resting T cells is lacking in
the literature. In fact, resting cells (CD25
) have been
reported to be refractory to entry by R5 viruses, presumably due to low
or absent coreceptor expression (7). Therefore, the presence
of R5 viruses within resting T cells that are themselves refractory to
direct infection would support a model in which the reservoir is
established through the infection of an activated T cell, which then
exits the cell cycle into a quiescent state. To test this hypothesis,
the chemokine receptor utilization of viruses derived from latently
infected CD4+ T lymphocytes was determined and compared to
the capacity of these viruses to directly infect resting
CD4+ T lymphocytes.
The evolution of coreceptor utilization by HIV-1 throughout the course
of infection has been widely documented (1, 14) Viruses
involved in transmission are almost universally dependent upon CCR5, as
demonstrated by the profound resistance of individuals null at the CCR5
locus to infection by HIV-1 (16, 26, 37). In some patients,
disease progression correlates with a broadening of the repertoire of
chemokine receptors utilized by HIV-1 during infection (14).
The coreceptor utilization of viruses in the latent compartment has not
been systematically analyzed. At least some viruses cultured from the
resting CD4+ T-cell compartment in previous studies were
cytopathic or capable of forming syncytia in the MT-2 cell line
(12, 20). To determine the nature of the coreceptors
utilized by viruses in the latent reservoir, we cloned and analyzed the
phenotype of env genes amplified from viruses resident in
highly purified resting CD4+ T lymphocytes from nine
patients on HAART. We demonstrate here for the first time that viral
envelopes from the latent reservoir show predominant usage of the
coreceptor CCR5. This finding is consistent with the fact that the
reservoir is formed soon after infection, when virtually all of the
viruses have the R5 phenotype. The maintenance of R5 genomes in resting
cells likely ensures that a broadening of coreceptor utilization occurs
with disease progression, rather than a replacement of R5 viruses with
those of the X4 phenotype, since R5 viruses present early in infection will be stored in the latent reservoir thereafter. This may account for
the identification of R5 viruses in a patient with documented X4 virus
in the blood prior to study.
Interpreting the low frequency of viruses utilizing CXCR4 in the latent
reservoir is complicated by an incomplete understanding of the nature
of the viruses present in each individual studied prior to the
initiation of therapy and of the mechanism by which the viruses entered
the resting compartment. An undetectable level of circulating virus was
a requirement for inclusion in this study, prohibiting a comparison of
the virus in the periphery to that in the reservoir. Furthermore, not
all patients acquire virus of the X4 phenotype. Only patient 56 had
documented utilization of CXCR4 prior to HAART. The analysis of several
independently derived clones suggested that the bias against virus
utilizing CXCR4 was unlikely a result of inadequate sampling of the
reservoir. It is interesting to speculate that the cytopathology
associated with X4 viruses provides strong selection against entrance
into the reservoir, although such viruses can clearly enter the
reservoir. Utilization of additional "minor" coreceptors, such as
CCR3, STRL33, GPR15, and APJ, was also observed in envelopes from
several patients. While the biological relevance of this finding is
difficult to interpret without a better understanding of the role in
vivo of these receptors, our study suggests that these receptors do not play a universal role in the establishment of the latent reservoir.
Longitudinal analysis of the frequency of latently infected cells in
treated patients reveals a very slow decay of the virus in this
compartment (19, 51). While several mechanisms have been
discussed to explain the persistence of virus in this compartment, the
long life span of memory T cells in vivo likely plays an important role. As a result, an interesting feature of this reservoir is that it
appears to act as an archive of viral quasi species, containing viruses
from many points during the life history of infection. The analysis of
antiviral drug resistance conferring mutations from virus cultured from
the resting T lymphocytes of individuals on HAART provides support for
the archival nature of this compartment (20). Should therapy
fail or be discontinued, virus may reemerge from the latent compartment
and rekindle infection. In this setting the virus reestablishing
infection may not reflect the phenotype of the virus circulating
immediately prior to the initiation of therapy due to the fact that the
breakthrough infection may have been the result of archival virus
emerging from the latent reservoir. Thus, the phenotype of viruses in
the latent compartment may have clinical significance as a repository
representing all stages of the disease course even in the presence of
successful therapy.
To better understand the significance of R5 viruses in the latent
compartment, we next determined whether these same viruses had the
capacity to infect resting T lymphocytes directly. Highly purified
resting lymphocytes were assayed for levels of CCR5 sufficient to
mediate infection by the R5 virus Ba-L. We demonstrate that only a
small fraction of resting T cells express CCR5. Thus, HIV-1 can enter
only a subset of quiescent T cells, all of which had a memory
phenotype. The PCR analysis performed in this study suggests that
infection of resting cells by R5 virus is inefficient and likely
limited to the subset expressing detectable levels of CCR5. This is
supported by the concordance of an absence of CCR5 on naive T cells and
our inability to demonstrate infection of these populations by an R5
virus (35). Additionally, our ability to demonstrate
infection of resting cells only during infection at high multiplicity
is consistent with the infection's being restricted to a small
fraction of resting cells expressing CCR5. This is a likely explanation
for the discrepancy between our results and those of Chou et al.
(7), who were unable to detect infection of resting
CD4+ T cells by R5 viruses. That a larger inoculum of Ba-L
was required to achieve detectable levels of infection compared to an
X4 virus supports a quantitative role of coreceptor expression during
entry (34, 45).
While infection of resting cells is nonproductive, the molecular
processes preventing the production of progeny virions are less clear
and the subject of extensive study. The inability to complete the
process of reverse transcription (25, 46, 47), a block
preventing the import of the preintegration complex into the nucleus
(38), and the absence of a required cellular factor(s) (24) have all been proposed to explain the fate of the virus in an infected quiescent T lymphocyte. Our approach to detecting entry
into resting cells relied on two different PCRs detecting either the
early or late products of reverse transcription. This analysis was
useful in demonstrating the absence of activated cells in our
resting-cell population. Our ability to detect reverse transcription
products with primers that span the junction of the LTR and
gag suggests that reverse transcription in resting T cells
proceeds largely to completion over the course of several days. The
kinetics of this reaction are much slower than what has been reported
and observed by us for the infection of activated cells (11, 18,
30, 47). These results differ from studies in the literature that
conclude that the reverse transcription process does not proceed to
completion in resting T cells (25, 46, 47). We believe the
basis of this difference is the length of time over which infection was
monitored following the application of the virus. In our hands, the
reverse transcription process is largely incomplete at early time
points and proceeds to completion over the course of a few days.
Additionally, previous studies of the status of reverse transcription
reaction in resting cells from HIV-1-infected individuals clearly
demonstrate both the absence of a build-up of incompletely
reverse-transcribed genomes and the presence of full-length linear
double-stranded viral cDNA (5, 8).
Studies of quiescent lymphocytes can be complicated by the presence of
contaminating activated cells. It is unlikely that the infection
demonstrated in this study reflects infection of contaminating
activated cells for several reasons. The sorted populations used in
this study were obtained using technology that allows for the isolation
of cells from uninfected donors that are invariably greater than 99%
free of cells bearing the HLA-DR marker of activation. These cells have
been previously shown to be truly quiescent, as measured by the fact
they do not incorporate thymidine in culture or expresses thymidine
kinase (11). Finally, as discussed above, the design of our
experiments allowed us to distinguish the infection of activated and
resting cells on the basis of the kinetics of the reverse transcription reaction. As shown in Fig. 2, the synthesis of strong-stop DNA is
largely complete at 12 h postinfection, while the product
representing completion of reverse transcription is largely
undetectable. In contrast, the viral genome can undergo both reverse
transcription and integration during this time frame in activated T
cells. Thus, the infection of activated cells cannot account for a
significant amount of the signal produced during our experiments.
An understanding of the capacity of R5 viruses to enter quiescent T
lymphocytes and the chemokine receptor utilization of viruses that
comprise the latent reservoir together provide some insight into the
mechanisms by which the latent reservoir may arise. The experiments
presented here demonstrate that CCR5 exists at levels sufficient to
mediate infection of only a subset of resting memory T cells. The
discovery that the majority of viruses in resting T cells utilize CCR5
during infection was surprising due to the refractory nature of most
resting cells to infection by viruses of this phenotype. It is
interesting to speculate that the R5 viruses cloned from the resting
cells of patients only had the capacity to enter the latent compartment
through an activated T lymphocyte or a memory cell with continued
expression of CCR5. We demonstrate here that the R5 viruses that
comprise the latent reservoir in most patients cannot directly enter
the naive subset of resting CD4+ T cells. However, some of
the latent virus present in resting CD4+ T cells in vivo is
in naive cells. Taken together, these results suggest that latently
infected naive CD4+ T cells arise through a mechanism that
does not involve direct infection of resting naive cells. One
possibility is that some resting memory cells with integrated HIV-1 DNA
might revert to the naive phenotype. Such phenotypic reversion has been
observed in normal uninfected humans and in rodent systems (6, 28, 29). Infection of thymocytes is another possibility. Our results are consistent with other studies demonstrating the presence of R5
viruses in naive CD4+ T lymphocytes of HIV-1-infected
individuals (2, 32). The overall conclusion of this work is
that the latent reservoir for HIV-1 comprises mainly R5 viruses,
viruses that do not enter most resting CD4+ T cells. The
generation of the latent reservoir therefore likely proceeds through
infection of other cell populations such as activated CD4+
T cells that can convert to resting cells carrying integrated HIV-1
genomes that become latent when cells are in a resting state.
 |
ACKNOWLEDGMENTS |
This work was supported by NIH grants AI 43222 to R.F.S. and AI
40880 to R.W.D.
We acknowledge Stuart Ray, Raj Gandi, Lucy Carruth, Monika Hermankova,
and remaining members of the Siliciano lab for helpful discussions. We
are also grateful to the individuals who donated the blood used in
these experiments.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Medicine, Johns Hopkins University School of Medicine, Ross Research Building 1049, 720 Rutland Avenue, Baltimore, MD 21205. Phone: (410)
955-2958. Fax: (410) 955-0964. E-mail:
rsilicia{at}welch.jhu.edu.
 |
REFERENCES |
| 1.
|
Berger, E. A.,
P. M. Murphy, and J. M. Farber.
1999.
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.
Annu. Rev. Immunol.
17:657-700[CrossRef][Medline].
|
| 2.
|
Blaak, H.,
A. B. van't Wout,
M. Brouwer,
B. Hooibrink,
E. Hovenkamp, and H. Schuitemaker.
2000.
In vivo HIV-1 infection of CD45RA+CD4+ T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4+ T cell decline.
Proc. Natl. Acad. Sci. USA
97:1269-1274[Abstract/Free Full Text].
|
| 3.
|
Bleul, C. C.,
L. Wu,
J. A. Hoxie,
T. A. Springer, and C. R. Mackay.
1997.
The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes [see comments].
Proc. Natl. Acad. Sci. USA
94:1925-1930[Abstract/Free Full Text].
|
| 4.
|
Bukrinsky, M. I.,
N. Sharova,
M. P. Dempsey,
T. L. Stanwick,
A. G. Bukrinskaya,
S. Haggerty, and M. Stevenson.
1992.
Active nuclear import of human immunodeficiency virus type 1 preintegration complexes.
Proc. Natl. Acad. Sci. USA
89:6580-6584[Abstract/Free Full Text].
|
| 5.
|
Bukrinsky, M. I.,
T. L. Stanwick,
M. P. Dempsey, and M. Stevenson.
1991.
Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection.
Science
254:423-427[Abstract/Free Full Text].
|
| 6.
|
Bunce, C., and E. B. Bell.
1997.
CD45RC isoforms define two types of CD4 memory T cells, one of which depends on persisting antigen.
J. Exp. Med.
185:767-776[Abstract/Free Full Text].
|
| 7.
|
Chou, C. S.,
O. Ramilo, and E. S. Vitetta.
1997.
Highly purified CD25 resting T cells cannot be infected de novo with HIV-1.
Proc. Natl. Acad. Sci. USA
94:1361-1365[Abstract/Free Full Text].
|
| 8.
|
Chun, T. W.,
L. Carruth,
D. Finzi,
X. Shen,
J. A. DiGiuseppe,
H. Taylor,
M. Hermankova,
K. Chadwick,
J. Margolick,
T. C. Quinn,
Y. H. Kuo,
R. Brookmeyer,
M. A. Zeiger,
C. P. Barditch, and R. F. Siliciano.
1997.
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.
Nature
387:183-188[CrossRef][Medline].
|
| 9.
|
Chun, T. W.,
K. Chadwick,
J. Margolick, and R. F. Siliciano.
1997.
Differential susceptibility of naive and memory CD4+ T cells to the cytopathic effects of infection with human immunodeficiency virus type 1 strain LAI.
J. Virol.
71:4436-4444[Abstract].
|
| 10.
|
Chun, T. W.,
D. Engel,
M. M. Berrey,
T. Shea,
L. Corey, and A. S. Fauci.
1998.
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.
Proc. Natl. Acad. Sci. USA
95:8869-8873[Abstract/Free Full Text].
|
| 11.
|
Chun, T. W.,
D. Finzi,
J. Margolick,
K. Chadwick,
D. Schwartz, and R. F. Siliciano.
1995.
In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency.
Nat. Med.
1:1284-1290[CrossRef][Medline].
|
| 12.
|
Chun, T. W.,
L. Stuyver,
S. B. Mizell,
L. A. Ehler,
J. A. Mican,
M. Baseler,
A. L. Lloyd,
M. A. Nowak, and A. S. Fauci.
1997.
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.
Proc. Natl. Acad. Sci. USA
94:13193-13197[Abstract/Free Full Text].
|
| 13.
|
Connor, R. I.,
B. K. Chen,
S. Choe, and N. R. Landau.
1995.
Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes.
Virology
206:935-944[CrossRef][Medline].
|
| 14.
|
Connor, R. I.,
K. E. Sheridan,
D. Ceradini,
S. Choe, and N. R. Landau.
1997.
Change in coreceptor use correlates with disease progression in HIV-1-infected individuals.
J. Exp. Med.
185:621-628[Abstract/Free Full Text].
|
| 15.
|
Crabtree, G. R.
1989.
Contingent genetic regulatory events in T lymphocyte activation.
Science
243:355-361[Abstract/Free Full Text].
|
| 16.
|
Dean, M.,
M. Carrington,
C. Winkler,
G. A. Huttley,
M. W. Smith,
R. Allikmets,
J. J. Goedert,
S. P. Buchbinder,
E. Vittinghoff,
E. Gomperts,
S. Donfield,
D. Vlahov,
R. Kaslow,
A. Saah,
C. Rinaldo,
R. Detels, and S. J. OBrien.
1996.
Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.
Science
273:1856-1862[Abstract/Free Full Text]. (Erratum, 274:1069.)
|
| 17.
|
Doranz, B. J.,
J. Rucker,
Y. Yi,
R. J. Smyth,
M. Samson,
S. C. Peiper,
M. Parmentier,
R. G. Collman, and R. W. Doms.
1996.
A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.
Cell
85:1149-1158[CrossRef][Medline].
|
| 18.
|
Farnet, C. M., and W. A. Haseltine.
1990.
Integration of human immunodeficiency virus type 1 DNA in vitro.
Proc. Natl. Acad. Sci. USA
87:4164-4168[Abstract/Free Full Text].
|
| 19.
|
Finzi, D.,
J. Blankson,
J. D. Siliciano,
J. B. Margolick,
K. Chadwick,
T. Pierson,
K. Smith,
J. Lisziewicz,
F. Lori,
C. Flexner,
T. C. Quinn,
R. E. Chaisson,
E. Rosenberg,
B. Walker,
S. Gange,
J. Gallant, and R. F. Siliciano.
1999.
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.
Nat. Med.
5:512-517[CrossRef][Medline].
|
| 20.
|
Finzi, D.,
M. Hermankova,
T. Pierson,
L. M. Carruth,
C. Buck,
R. E. Chaisson,
T. C. Quinn,
K. Chadwick,
J. Margolick,
R. Brookmeyer,
J. Gallant,
M. Markowitz,
D. D. Ho,
D. D. Richman, and R. F. Siliciano.
1997.
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.
Science
278:1295-1300[Abstract/Free Full Text].
|
| 21.
|
Gowda, S. D.,
B. S. Stein,
N. Mohagheghpour,
C. J. Benike, and E. G. Engleman.
1989.
Evidence that T cell activation is required for HIV-1 entry in CD4+ lymphocytes.
J. Immunol.
142:773-780[Abstract].
|
| 22.
|
Guignard, F.,
C. Combadiere,
H. L. Tiffany, and P. M. Murphy.
1998.
Gene organization and promoter function for CC chemokine receptor 5 (CCR5).
J. Immunol.
160:985-992[Abstract/Free Full Text].
|
| 23.
|
Helbert, M. R.,
J. Walter,
J. LAge, and P. C. Beverley.
1997.
HIV infection of CD45RA+ and CD45RO+ CD4+ T cells.
Clin. Exp. Immunol.
107:300-305[CrossRef][Medline].
|
| 24.
|
Kinoshita, S.,
B. K. Chen,
H. Kaneshima, and G. P. Nolan.
1998.
Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells.
Cell
95:595-604[CrossRef][Medline].
|
| 25.
|
Korin, Y. D., and J. A. Zack.
1998.
Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells.
J. Virol.
72:3161-3168[Abstract/Free Full Text].
|
| 26.
|
Liu, R.,
W. A. Paxton,
S. Choe,
D. Ceradini,
S. R. Martin,
R. Horuk,
M. E. MacDonald,
H. Stuhlmann,
R. A. Koup, and N. R. Landau.
1996.
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection.
Cell
86:367-377[CrossRef][Medline].
|
| 27.
|
Lori, F.,
F. di Marzo Veronese,
A. L. De Vico,
P. Lusso,
M. S. Reitz, Jr., and R. C. Gallo.
1992.
Viral DNA carried by human immunodeficiency virus type 1 virions.
J. Virol.
66:5067-5074[Abstract/Free Full Text].
|
| 28.
|
Mclean, A. R., and C. A. Michie.
1995.
In vivo estimates of division and death rates of human T lymphocytes.
Proc. Natl. Acad. Sci. USA
92:3707-3711[Abstract/Free Full Text].
|
| 29.
|
Michie, C. A.,
A. McLean,
C. Alcock, and P. C. Beverley.
1992.
Lifespan of human lymphocyte subsets defined by CD45 isoforms.
Nature
360:264-265[CrossRef][Medline].
|
| 30.
|
Miller, M. D.,
C. M. Farnet, and F. D. Bushman.
1997.
Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition.
J. Virol.
71:5382-5390[Abstract].
|
| 31.
|
Moriuchi, H.,
M. Moriuchi, and A. S. Fauci.
1997.
Cloning and analysis of the promoter region of CCR5, a coreceptor for HIV-1 entry.
J. Immunol.
159:5441-5449[Abstract].
|
| 32.
|
Ostrowski, M. A.,
T. W. Chun,
S. J. Justement,
I. Motola,
M. A. Spinelli,
J. Adelsberger,
L. A. Ehler,
S. B. Mizell,
C. W. Hallahan, and A. S. Fauci.
1999.
Both memory and CD45RA+/CD62L+ naive CD4(+) T cells are infected in human immunodeficiency virus type 1-infected individuals.
J. Virol.
73:6430-6435[Abstract/Free Full Text].
|
| 33.
|
Pierson, T.,
J. McArthur, and R. F. Siliciano.
2000.
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Annu. Rev. Immunol.
18:665-708[CrossRef][Medline].
|
| 34.
|
Platt, E. J.,
K. Wehrly,
S. E. Kuhmann,
B. Chesebro, and D. Kabat.
1998.
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophage-tropic isolates of human immunodeficiency virus type 1.
J. Virol.
72:2855-2864[Abstract/Free Full Text].
|
| 35.
|
Rabin, R. L.,
M. K. Park,
F. Liao,
R. Swofford,
D. Stephany, and J. M. Farber.
1999.
Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling.
J. Immunol.
162:3840-3850[Abstract/Free Full Text].
|
| 36.
|
Roederer, M.,
P. A. Raju,
D. K. Mitra, and L. A. Herzenberg.
1997.
HIV does not replicate in naive CD4 T cells stimulated with CD3/CD28.
J. Clin. Investig.
99:1555-1564[Medline].
|
| 37.
|
Samson, M.,
F. Libert,
B. J. Doranz,
J. Rucker,
C. Liesnard,
C. M. Farber,
S. Saragosti,
C. Lapoumeroulie,
J. Cognaux,
C. Forceille,
G. Muyldermans,
C. Verhofstede,
G. Burtonboy,
M. Georges,
T. Imai,
S. Rana,
Y. Yi,
R. J. Smyth,
R. G. Collman,
R. W. Doms,
G. Vassart, and M. Parmentier.
1996.
Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.
Nature
382:722-725[CrossRef][Medline].
|
| 38.
|
Stevenson, M.,
T. L. Stanwick,
M. P. Dempsey, and C. A. Lamonica.
1990.
HIV-1 replication is controlled at the level of T cell activation and proviral integration.
EMBO J.
9:1551-1560[Medline].
|
| 39.
|
Tang, S.,
B. Patterson, and J. A. Levy.
1995.
Highly purified quiescent human peripheral blood CD4+ T cells are infectible by human immunodeficiency virus but do not release virus after activation.
J. Virol.
69:5659-5665[Abstract].
|
| 40.
|
Trono, D.
1992.
Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses.
J. Virol.
66:4893-4900[Abstract/Free Full Text].
|
| 41.
|
Unutmaz, D.,
V. N. KewalRamani,
S. Marmon, and D. R. Littman.
1999.
Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes.
J. Exp. Med.
189:1735-1746[Abstract/Free Full Text].
|
| 42.
|
Wild, C.,
T. Oas,
C. McDanal,
D. Bolognesi, and T. Matthews.
1992.
A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.
Proc. Natl. Acad. Sci. USA
89:10537-10541[Abstract/Free Full Text].
|
| 43.
|
Wong, J. K.,
M. Hezareh,
H. F. Günthard,
D. V. Havlir,
C. C. Ignacio,
C. A. Spina, and D. D. Richman.
1997.
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.
Science
278:1291-1295[Abstract/Free Full Text].
|
| 44.
|
Woods, T. C.,
B. D. Roberts,
S. T. Butera, and T. M. Folks.
1997.
Loss of inducible virus in CD45RA naive cells after human immunodeficiency virus-1 entry accounts for preferential viral replication in CD45RO memory cells.
Blood
89:1635-1641[Abstract/Free Full Text].
|
| 45.
|
Wu, L.,
W. A. Paxton,
N. Kassam,
N. Ruffing,
J. B. Rottman,
N. Sullivan,
H. Choe,
J. Sodroski,
W. Newman,
R. A. Koup, and C. R. Mackay.
1997.
CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro.
J. Exp. Med.
185:1681-1691[Abstract/Free Full Text].
|
| 46.
|
Zack, J. A.,
S. J. Arrigo,
S. R. Weitsman,
A. S. Go,
A. Haislip, and I. S. Chen.
1990.
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.
Cell
61:213-222[CrossRef][Medline].
|
| 47.
|
Zack, J. A.,
A. M. Haislip,
P. Krogstad, and I. S. Chen.
1992.
Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle.
J. Virol.
66:1717-1725[Abstract/Free Full Text].
|
| 48.
|
Zhang, H.,
O. Bagasra,
M. Niikura,
B. J. Poiesz, and R. J. Pomerantz.
1994.
Intravirion reverse transcripts in the peripheral blood plasma of human immunodeficiency virus type 1-infected individuals.
J. Virol.
68:7591-7597[Abstract/Free Full Text].
|
| 49.
|
Zhang, H.,
Y. Zhang,
T. Spicer,
D. Henrard, and B. J. Poiesz.
1995.
Nascent human immunodeficiency virus type 1 reverse transcription occurs within an enveloped particle.
J. Virol.
69:3675-3682[Abstract].
|
| 50.
|
Zhang, H.,
Y. Zhang,
T. P. Spicer,
L. Z. Abbott,
M. Abbott, and B. J. Poiesz.
1993.
Reverse transcription takes place within extracellular HIV-1 virions: potential biological significance.
AIDS Res. Hum. Retroviruses
9:1287-1296[Medline].
|
| 51.
|
Zhang, L.,
B. Ramratnam,
R. K. Tenner,
Y. He,
M. Vesanen,
S. Lewin,
A. Talal,
P. Racz,
A. S. Perelson,
B. T. Korber,
M. Markowitz, and D. D. Ho.
1999.
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.
N. Engl. J. Med.
340:1605-1613[Abstract/Free Full Text].
|
Journal of Virology, September 2000, p. 7824-7833, Vol. 74, No. 17
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Dai, J., Agosto, L. M., Baytop, C., Yu, J. J., Pace, M. J., Liszewski, M. K., O'Doherty, U.
(2009). Human Immunodeficiency Virus Integrates Directly into Naive Resting CD4+ T Cells but Enters Naive Cells Less Efficiently than Memory Cells. J. Virol.
83: 4528-4537
[Abstract]
[Full Text]
-
Zhou, Y., Shen, L., Yang, H.-C., Siliciano, R. F.
(2008). Preferential Cytolysis of Peripheral Memory CD4+ T Cells by In Vitro X4-Tropic Human Immunodeficiency Virus Type 1 Infection before the Completion of Reverse Transcription. J. Virol.
82: 9154-9163
[Abstract]
[Full Text]
-
Saleh, S., Solomon, A., Wightman, F., Xhilaga, M., Cameron, P. U., Lewin, S. R.
(2007). CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood
110: 4161-4164
[Abstract]
[Full Text]
-
Bailey, J. R., Sedaghat, A. R., Kieffer, T., Brennan, T., Lee, P. K., Wind-Rotolo, M., Haggerty, C. M., Kamireddi, A. R., Liu, Y., Lee, J., Persaud, D., Gallant, J. E., Cofrancesco, J. Jr., Quinn, T. C., Wilke, C. O., Ray, S. C., Siliciano, J. D., Nettles, R. E., Siliciano, R. F.
(2006). Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells.. J. Virol.
80: 6441-6457
[Abstract]
[Full Text]
-
Fernandez, G., Llano, A., Esgleas, M., Clotet, B., Este, J. A., Martinez, M. A.
(2006). Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses.. J. Gen. Virol.
87: 1285-1294
[Abstract]
[Full Text]
-
Bailey, J. R., Lassen, K. G., Yang, H.-C., Quinn, T. C., Ray, S. C., Blankson, J. N., Siliciano, R. F.
(2006). Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy.. J. Virol.
80: 4758-4770
[Abstract]
[Full Text]
-
Kim, Y.-S., Kim, J.-M., Jung, D.-L., Kang, J.-E., Lee, S., Kim, J. S., Seol, W., Shin, H.-C., Kwon, H. S., Van Lint, C., Hernandez, N., Hur, M.-W.
(2005). Artificial Zinc Finger Fusions Targeting Sp1-binding Sites and the trans-Activator-responsive Element Potently Repress Transcription and Replication of HIV-1. J. Biol. Chem.
280: 21545-21552
[Abstract]
[Full Text]
-
Joshi, A., Garg, H., Tompkins, M. B., Tompkins, W. A.
(2005). Preferential Feline Immunodeficiency Virus (FIV) Infection of CD4+ CD25+ T-Regulatory Cells Correlates both with Surface Expression of CXCR4 and Activation of FIV Long Terminal Repeat Binding Cellular Transcriptional Factors. J. Virol.
79: 4965-4976
[Abstract]
[Full Text]
-
Noe, A., Plum, J., Verhofstede, C.
(2005). The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance. J Antimicrob Chemother
55: 410-412
[Abstract]
[Full Text]
-
Zhou, Y., Zhang, H., Siliciano, J. D., Siliciano, R. F.
(2005). Kinetics of Human Immunodeficiency Virus Type 1 Decay following Entry into Resting CD4+ T Cells. J. Virol.
79: 2199-2210
[Abstract]
[Full Text]
-
Lassen, K. G., Bailey, J. R., Siliciano, R. F.
(2004). Analysis of Human Immunodeficiency Virus Type 1 Transcriptional Elongation in Resting CD4+ T Cells In Vivo. J. Virol.
78: 9105-9114
[Abstract]
[Full Text]
-
Han, Y., Lassen, K., Monie, D., Sedaghat, A. R., Shimoji, S., Liu, X., Pierson, T. C., Margolick, J. B., Siliciano, R. F., Siliciano, J. D.
(2004). Resting CD4+ T Cells from Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals Carry Integrated HIV-1 Genomes within Actively Transcribed Host Genes. J. Virol.
78: 6122-6133
[Abstract]
[Full Text]
-
Segal, D. J., Goncalves, J., Eberhardy, S., Swan, C. H., Torbett, B. E., Li, X., Barbas, C. F. III
(2004). Attenuation of HIV-1 Replication in Primary Human Cells with a Designed Zinc Finger Transcription Factor. J. Biol. Chem.
279: 14509-14519
[Abstract]
[Full Text]
-
Ohagen, A., Devitt, A., Kunstman, K. J., Gorry, P. R., Rose, P. P., Korber, B., Taylor, J., Levy, R., Murphy, R. L., Wolinsky, S. M., Gabuzda, D.
(2003). Genetic and Functional Analysis of Full-Length Human Immunodeficiency Virus Type 1 env Genes Derived from Brain and Blood of Patients with AIDS. J. Virol.
77: 12336-12345
[Abstract]
[Full Text]
-
Havlir, D. V., Strain, M. C., Clerici, M., Ignacio, C., Trabattoni, D., Ferrante, P., Wong, J. K.
(2003). Productive Infection Maintains a Dynamic Steady State of Residual Viremia in Human Immunodeficiency Virus Type 1-Infected Persons Treated with Suppressive Antiretroviral Therapy for Five Years. J. Virol.
77: 11212-11219
[Abstract]
[Full Text]
-
Hermankova, M., Siliciano, J. D., Zhou, Y., Monie, D., Chadwick, K., Margolick, J. B., Quinn, T. C., Siliciano, R. F.
(2003). Analysis of Human Immunodeficiency Virus Type 1 Gene Expression in Latently Infected Resting CD4+ T Lymphocytes In Vivo. J. Virol.
77: 7383-7392
[Abstract]
[Full Text]
-
Shen, A., Zink, M. C., Mankowski, J. L., Chadwick, K., Margolick, J. B., Carruth, L. M., Li, M., Clements, J. E., Siliciano, R. F.
(2003). Resting CD4+ T Lymphocytes but Not Thymocytes Provide a Latent Viral Reservoir in a Simian Immunodeficiency Virus-Macaca nemestrina Model of Human Immunodeficiency Virus Type 1-Infected Patients on Highly Active Antiretroviral Therapy. J. Virol.
77: 4938-4949
[Abstract]
[Full Text]
-
Strain, M. C., Gunthard, H. F., Havlir, D. V., Ignacio, C. C., Smith, D. M., Leigh-Brown, A. J., Macaranas, T. R., Lam, R. Y., Daly, O. A., Fischer, M., Opravil, M., Levine, H., Bacheler, L., Spina, C. A., Richman, D. D., Wong, J. K.
(2003). Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: Intrinsic stability predicts lifelong persistence. Proc. Natl. Acad. Sci. USA
100: 4819-4824
[Abstract]
[Full Text]
-
Persaud, D., Zhou, Y., Siliciano, J. M., Siliciano, R. F.
(2003). Latency in Human Immunodeficiency Virus Type 1 Infection: No Easy Answers. J. Virol.
77: 1659-1665
[Full Text]
-
Scripture-Adams, D. D., Brooks, D. G., Korin, Y. D., Zack, J. A.
(2002). Interleukin-7 Induces Expression of Latent Human Immunodeficiency Virus Type 1 with Minimal Effects on T-Cell Phenotype. J. Virol.
76: 13077-13082
[Abstract]
[Full Text]
-
Pierson, T. C., Zhou, Y., Kieffer, T. L., Ruff, C. T., Buck, C., Siliciano, R. F.
(2002). Molecular Characterization of Preintegration Latency in Human Immunodeficiency Virus Type 1 Infection. J. Virol.
76: 8518-8531
[Abstract]
[Full Text]
-
Kutsch, O., Benveniste, E. N., Shaw, G. M., Levy, D. N.
(2002). Direct and Quantitative Single-Cell Analysis of Human Immunodeficiency Virus Type 1 Reactivation from Latency. J. Virol.
76: 8776-8786
[Abstract]
[Full Text]
-
Muller, V., Vigueras-Gomez, J. F., Bonhoeffer, S.
(2002). Decelerating Decay of Latently Infected Cells during Prolonged Therapy for Human Immunodeficiency Virus Type 1 Infection. J. Virol.
76: 8963-8965
[Abstract]
[Full Text]
-
Ghose, R., Liou, L.-Y., Herrmann, C. H., Rice, A. P.
(2001). Induction of TAK (Cyclin T1/P-TEFb) in Purified Resting CD4+ T Lymphocytes by Combination of Cytokines. J. Virol.
75: 11336-11343
[Abstract]
[Full Text]
-
Saphire, A. C. S., Bobardt, M. D., Zhang, Z., David, G., Gallay, P. A.
(2001). Syndecans Serve as Attachment Receptors for Human Immunodeficiency Virus Type 1 on Macrophages. J. Virol.
75: 9187-9200
[Abstract]
[Full Text]
-
Martín, J., LaBranche, C. C., González-Scarano, F.
(2001). Differential CD4/CCR5 Utilization, gp120 Conformation, and Neutralization Sensitivity between Envelopes from a Microglia-Adapted Human Immunodeficiency Virus Type 1 and Its Parental Isolate. J. Virol.
75: 3568-3580
[Abstract]
[Full Text]
-
Motsinger, A., Haas, D. W., Stanic, A. K., Van Kaer, L., Joyce, S., Unutmaz, D.
(2002). CD1d-restricted Human Natural Killer T Cells Are Highly Susceptible to Human Immunodeficiency Virus 1 Infection. JEM
195: 869-879
[Abstract]
[Full Text]